Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma


FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the DecisionDx®-Melanoma gene expression profile (GEP) test accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node b